Home / Conditions / Autoimmune Disease
Autoimmune Disease: when insurers say no, reviewers often say yes
In 122 published external-review decisions involving autoimmune disease, independent physician reviewers overturned the insurer’s denial 63.1% of the time.
Published decisions
122
2001–2026
Overturned
63.1%
77 denials reversed
Most-fought treatments for autoimmune disease
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| IVIG Therapy | 51 | 56.9% |
| Biologics | 22 | 90.9% |
| Anti-inflammatories | 7 | 57.1% |
| Skin Treatment | 5 | 100% |
| Hormones | 3 | 33.3% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 98 | 64.3% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 24 | 58.3% |
Typical time to a decision
6 days
Most land between 3 and 20 days
Handled as urgent
68%
Expedited when a delay would cause harm
Recent direction
Rising
53.7% → 75.9% overturned, last three years
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: An enrollee’s parent has requested reimbursement and prospective authorization and coverage for intravenous immunoglobulin (IVIG) infusions (Gammagard 86 grams divided over three days every four weeks) provided, and prospective authorization and coverage for IVIG infusions (Gammagard 86 grams divided over three days every four weeks). Pediatric acute-onset neuropsychiatric syndrome (PANS) is defined by the sudden onset of obsessive compulsive disorder (OCD) or eating restrictions and comorbid symptoms. Acute onset cases that are triggered by Group A streptococcal infections may meet diagnostic criteria for both PANS and pediatric autoimmune neuropsychiatric disorder associated with streptococcus (PANDAS). These two syndromes display highly similar symptoms and guidelines often treat them as a single entity (Thienemann, et al.).
Nature of Statutory Criteria/Case Summary: The patient is a 13-year-old female with a diagnosis of irritable bowel syndrome-constipation subtype. She also has a history of dysautonomia and vasovagal syncope, dizziness, and postural orthostatic tachycardia syndrome. The medical records note the patient has struggled with constipation since she was six months of age and has been treated with MiraLAX since that time. An esophagogastroduodenoscopy (EGD) and colonoscopy in showed focal active ileitis with a single ill-defined granuloma. A magnetic resonance elastography (MRE) in was noted to be normal. The patient was treated with budesonide for a couple months, but symptoms persisted/worsened. Despite MiraLAX, one cap daily, the patient was noted to have bowel movements from twice daily to (more commonly) once weekly. She also takes senna as needed. Imaging showed moderate constipation.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Acthar Gel.Findings: The physician reviewer found that American College of Rheumatology guideline on the treatment of psoriatic arthritis notes, “In treatment-naive patients with active psoriatic arthritis (PsA), a tumor necrosis factor inhibitor (TNFi) biologic agent is recommended over an oral small molecule (OSM) as a first-line option. OSMs may be used instead of a TNFi biologic in patients without severe PsA and without severe psoriasis, those who prefer an oral drug instead of parenteral therapy, or those with contraindications to TNFi treatment, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease.
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for genetic testing services [F5 (coagulation factor V) (e.g. hereditary hypercoagulability) gene analysis, Leiden variant; F2 (prothrombin, coagulation factor II) (e.g. hereditary hypercoagulability) gene analysis, 20210G>A variant; and MTHFR (5,10-methylenetetrahydrofolate reductase) (e.g. hereditary hypercoagulability) gene analysis, common variants (e.g. 677T, 1298C)]. There is a lack of evidence to support the use of the services at issue for the diagnosis or management of hypothyroidism or low testosterone. Genetic testing is not part of the diagnosis or treatment of hypothyroidism or low testosterone.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
How to use this in your appeal
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for autoimmune disease was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.